文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌单次大剂量率近距离放疗:SiFEPI II期前瞻性试验结果

Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2022-08-18

SiFEPI II期前瞻性试验评估低危和有利中危前列腺癌患者接受单次20 Gy大剂量率近距离放疗的疗效与毒性。2014年3月至2017年10月入组35例,33例可评估。中位随访72.8个月,6年生化无复发生存率为62%,晚期泌尿生殖和胃肠道毒性以1级为主,但生化控制欠佳。

要点

  • 晚期泌尿生殖毒性33%均为1级,胃肠道毒性12%均为1级,性毒性21%。
  • 33例中11例(33%)出现生化复发,其中82%为组织学证实的孤立局部复发。

核心结论

  • SiFEPI试验的长期结果显示,单次20 Gy大剂量率近距离放疗对低危和有利中危前列腺癌的生化控制欠佳。
  • 晚期泌尿生殖和胃肠道毒性特征令人鼓舞,使得大剂量率近距离放疗被认为是一种安全的放疗技术。

研究设计与样本

  • SiFEPI(NCT02104362)为II期前瞻性试验,评估单次大剂量率近距离放疗用于低危和有利中危前列腺癌。
  • 直肠间隔物置入后,单次20 Gy照射前列腺。
  • 2014年3月至2017年10月入组35例,33例可评估;中位年龄66岁(范围46-79),低危25例(76%),有利中危8例(24%)。
  • 中位随访72.8个月(范围64-86)。

主要发现

  • 晚期泌尿生殖毒性11例(33%;18例次1级),胃肠道毒性4例(12%;4例次1级),性毒性7例(21%;1例次1级、5例次2级、1例次3级)。
  • 生化复发11例(33%;低危7例,有利中危4例),大剂量率近距离放疗至生化复发的中位时间为51个月(范围24-69)。
  • 11例生化复发患者中9例(82%)为组织学证实的孤立局部复发。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the results of the Single Fraction Early Prostate Irradiation (SiFEPI) phase 2 prospective trial. MATERIALS/METHODS: The SiFEPI trial (NCT02104362) evaluated a single fraction of high-dose rate brachytherapy (HDB) for low- (LR) and favorable-intermediate (FIR) risk prostate cancers. After rectal spacer placement, a single fraction of 20 Gy was delivered to the prostate. Oncological outcome (biochemical (bRFS) and local (lRFS) relapses, disease-free (DFS) and overall (OS) survivals and toxicity (acute/late genito-urinary (GU), gastro-intestinal (GI) and sexual (S) toxicities were investigated. RESULTS: From 03/2014 to 10/2017, 35 pts were enrolled, of whom 33 were evaluable. With a median age of 66 y [46-79], 25 (76 %) and 8 (24 %) pts were LR and FIR respectively. With a MFU of 72.8 months [64-86], 6y-bRFS, lRFS and mRFS were 62 % [45-85], 61 % [44-85] and 93 % [85-100] respectively while 6y-DFS, CSS and OS were 54 % [37-77], 100 % and 89 % [77-100] respectively. Late GU, GI and S toxicities were observed in 11 pts (33 %;18G1), 4 pts (12 %;4G1) and 7 pts (21 %;1G1,5G2,1G3) respectively. Biochemical relapse (BR) was observed in 11 pts (33 %;7LR,4FIR) with a median time interval between HDB and BR of 51 months [24-69]. Nine of these pts (82 %) presented a histologically proven isolated local recurrence. CONCLUSIONS: Long-term results of the SiFEPI trial show that a single fraction of 20 Gy leads to sub-optimal biochemical control for LR/FIR prostate cancers. The late GU and GI toxicity profile is encouraging, leading to consideration of HDB as a safe irradiation technique.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hannoun-Levi JM, Chand-Fouche ME, Pace-Loscos T, et al. Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial. Clin Transl Radiat Oncol. 2022. PMID: 36093342. doi:10.1016/j.ctro.2022.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。